Gozetotide (Locametz)
- Status:
- Do Not Prescribe (DNP)
- Decision Date:
- October 2022
Comments
DNP:
- Treatment of partial thickness wounds associated with dystrophic and
junctional epidermolysis bullosa in patients aged ≥6 month
- Identification of prostate-specific membrane antigen-positive lesions by
positron emission tomography in adults with prostate cancer, after
radiolabelling with gallium-68. Await clinician request or national guidance. (Decision date - November 2022)
search again